SCHEMBL734958

SCHEMBL734958

CCCCCCc1cnccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KCNH2 Q12809 1/20 0.47
KDM4E B2RXH2 2/20 0.45
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TLR7 Q9NYK1 2/20 0.39
TRPV1 Q8NER1 5/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27678203 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL9752654 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL19304404 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL16115136 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL15573513 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL5138548 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL28390769 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL15376927 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL1325052 0.98 TDP1 (0.48) TDP1L3MBTL1KCNH2KDM4ECYP2D6
SCHEMBL4412197 0.92 CYP2D6 (0.43) TDP1L3MBTL1KCNH2KDM4ECYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 EP disclosed
US-11993674-B2 Functional resin material, manufacturing method thereof, and moisture-sensed shrinking fabric TAIWAN TEXTILE RESEARCH INSTITUTE (TW) 2024-05-28 US disclosed
EP-2775839-B1 METHODS FOR ASSESSING REPELLANT QUALITY OF ORGANIC MATERIALS AND METHODS AND COMPOSITIONS FOR REPELLING ARTHROPODS UNIV CALIFORNIA (US) 2023-12-06 EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 WO disclosed
US-20220010050-A1 FUNCTIONAL RESIN MATERIAL, MANUFACTURING METHOD THEREOF, AND MOISTURE-SENSED SHRINKING FABRIC TAIWAN TEXTILE RESEARCH INSTITUTE (TW) 2022-01-13 US disclosed
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2019-06-04 US disclosed
US-20180223330-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-08-09 US disclosed
EP-2067782-B2 HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND THEIR PRODUCTION METHODS TOSOH CORP (JP) 2018-06-27 EP disclosed
US-9963450-B2 A3 adenosine receptor agonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-05-08 US disclosed
EP-2775839-A2 METHODS FOR ASSESSING REPELLANT QUALITY OF ORGANIC MATERIALS AND METHODS AND COMPOSITIONS FOR REPELLING ARTHROPODS The Regents of The University of California (US) 2014-09-17 EP disclosed
US-20080280836-A1 Anti-hypercholesterolemic biaryl azetidinone compounds MORRIELLO GREGORI J 2008-11-13 US disclosed
EP-1587863-A1 NETWORK SILICA FOR ENHANCING TENSILE STRENGTH OF RUBBER COMPOUND Republic of Korea (Chonnam National University) (KR) 2005-10-26 EP disclosed
WO-2004078835-A1 NETWORK SILICA FOR ENHANCING TENSILE STRENGTH OF RUBBER COMPOUND REPUBLIC OF KOREA(CHONNAM NATIONAL UNIVERSITY) (KR) 2004-09-16 WO disclosed
EP-0637323-B1 COPOLYMERS AND NON-POROUS, SEMI-PERMEABLE MEMBRANE THEREOF AND ITS USE FOR PERMEATING MOLECULES OF PREDETERMINED MOLECULAR WEIGHT RANGE POLYMER TECHNOLOGY GROUP INC (US) 1998-08-19 EP disclosed
US-5403877-A Salts of triazine derivatives with oxygenated acids of phosphorus and their use in self-extinguishing polymeric compositions MINISTERO DELL'UNIVERSITA E DELLA RICERCA SCIENTIFICA E. TECNOLOGICA (IT) 1995-04-04 US disclosed
US-4871848-A OIL, GAS WELLS CORROSION INHIBITORS THE DOW CHEMICAL COMPANY (US) 1989-10-03 US disclosed
US-4740320-A REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE THE DOW CHEMICAL COMPANY (US) 1988-04-26 US disclosed
US-4725373-A CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-02-16 US disclosed
US-4724003-A Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines THE DOW CHEMICAL COMPANY (US) 1988-02-09 US disclosed
US-4676834-A Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone THE DOW CHEMICAL COMPANY (US) 1987-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280836-A1 Anti-hypercholesterolemic biaryl azetidinone compounds APOB, PCSK9, CYP46A1 TDP1 4349/4885L3MBTL1 3411/4885KCNH2 500/4885
US-20180223330-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 TDP1 3852/4885L3MBTL1 52/4885KCNH2 1711/4885
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates AADAC, PGLS, GLB1 TDP1 3491/4885L3MBTL1 241/4885KCNH2 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.